Anti-growth factor therapy for lung cancer

Daniel C. Chan, Mark Geraci, Paul A. Bunn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Lung cancers are the leading cause of cancer death in developed countries. In the USA, lung cancer accounts for 29% of all cancer deaths. The cure rate for lung cancer is low (14%) because the cancer spreads early and because chemotherapy cannot cure metastatic disease. In small cell lung cancer (SCLC) two-thirds of patients present with metastatic disease in a distant organ (stage IV). In non-small cell lung cancers (adenocarcinoma, squamous carcinoma, large cell carcinoma) one-third present with metastatic disease. Initial chemotherapy produces high response rates in both SCLC (85%-90% response rate) and NSCLC (50% response rate) but response duration is short and drug resistance develops rapidly. Growth factors play an important role in the pathogenesis and the progression of lung cancers. Knowledge of the role of these growth factors, their receptors and their signal pathways has produced new therapeutic targets. Compounds developed toward these targets have completed preclinical testing and are now in clinical trials. Some of these compounds are active in both drug sensitive and drug resistant lung cancers. They also produce synergistic growth inhibition when combined with cytotoxic chemotherapeutic agents. Thus, these compounds may provide a new way to overcome drug resistance in lung cancer.

Original languageEnglish (US)
Pages (from-to)377-388
Number of pages12
JournalDrug Resistance Updates
Volume1
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Small Cell Lung Carcinoma
Drug Resistance
Therapeutics
Large Cell Carcinoma
Drug Therapy
Neoplasms
Growth Factor Receptors
Cytotoxins
Developed Countries
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Cause of Death
Squamous Cell Carcinoma
Signal Transduction
Clinical Trials
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Pharmacology

Cite this

Anti-growth factor therapy for lung cancer. / Chan, Daniel C.; Geraci, Mark; Bunn, Paul A.

In: Drug Resistance Updates, Vol. 1, No. 6, 1998, p. 377-388.

Research output: Contribution to journalArticle

Chan, Daniel C. ; Geraci, Mark ; Bunn, Paul A. / Anti-growth factor therapy for lung cancer. In: Drug Resistance Updates. 1998 ; Vol. 1, No. 6. pp. 377-388.
@article{13755b9da53843c9a190604cd31b60ed,
title = "Anti-growth factor therapy for lung cancer",
abstract = "Lung cancers are the leading cause of cancer death in developed countries. In the USA, lung cancer accounts for 29{\%} of all cancer deaths. The cure rate for lung cancer is low (14{\%}) because the cancer spreads early and because chemotherapy cannot cure metastatic disease. In small cell lung cancer (SCLC) two-thirds of patients present with metastatic disease in a distant organ (stage IV). In non-small cell lung cancers (adenocarcinoma, squamous carcinoma, large cell carcinoma) one-third present with metastatic disease. Initial chemotherapy produces high response rates in both SCLC (85{\%}-90{\%} response rate) and NSCLC (50{\%} response rate) but response duration is short and drug resistance develops rapidly. Growth factors play an important role in the pathogenesis and the progression of lung cancers. Knowledge of the role of these growth factors, their receptors and their signal pathways has produced new therapeutic targets. Compounds developed toward these targets have completed preclinical testing and are now in clinical trials. Some of these compounds are active in both drug sensitive and drug resistant lung cancers. They also produce synergistic growth inhibition when combined with cytotoxic chemotherapeutic agents. Thus, these compounds may provide a new way to overcome drug resistance in lung cancer.",
author = "Chan, {Daniel C.} and Mark Geraci and Bunn, {Paul A.}",
year = "1998",
doi = "10.1016/S1368-7646(98)80013-7",
language = "English (US)",
volume = "1",
pages = "377--388",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Anti-growth factor therapy for lung cancer

AU - Chan, Daniel C.

AU - Geraci, Mark

AU - Bunn, Paul A.

PY - 1998

Y1 - 1998

N2 - Lung cancers are the leading cause of cancer death in developed countries. In the USA, lung cancer accounts for 29% of all cancer deaths. The cure rate for lung cancer is low (14%) because the cancer spreads early and because chemotherapy cannot cure metastatic disease. In small cell lung cancer (SCLC) two-thirds of patients present with metastatic disease in a distant organ (stage IV). In non-small cell lung cancers (adenocarcinoma, squamous carcinoma, large cell carcinoma) one-third present with metastatic disease. Initial chemotherapy produces high response rates in both SCLC (85%-90% response rate) and NSCLC (50% response rate) but response duration is short and drug resistance develops rapidly. Growth factors play an important role in the pathogenesis and the progression of lung cancers. Knowledge of the role of these growth factors, their receptors and their signal pathways has produced new therapeutic targets. Compounds developed toward these targets have completed preclinical testing and are now in clinical trials. Some of these compounds are active in both drug sensitive and drug resistant lung cancers. They also produce synergistic growth inhibition when combined with cytotoxic chemotherapeutic agents. Thus, these compounds may provide a new way to overcome drug resistance in lung cancer.

AB - Lung cancers are the leading cause of cancer death in developed countries. In the USA, lung cancer accounts for 29% of all cancer deaths. The cure rate for lung cancer is low (14%) because the cancer spreads early and because chemotherapy cannot cure metastatic disease. In small cell lung cancer (SCLC) two-thirds of patients present with metastatic disease in a distant organ (stage IV). In non-small cell lung cancers (adenocarcinoma, squamous carcinoma, large cell carcinoma) one-third present with metastatic disease. Initial chemotherapy produces high response rates in both SCLC (85%-90% response rate) and NSCLC (50% response rate) but response duration is short and drug resistance develops rapidly. Growth factors play an important role in the pathogenesis and the progression of lung cancers. Knowledge of the role of these growth factors, their receptors and their signal pathways has produced new therapeutic targets. Compounds developed toward these targets have completed preclinical testing and are now in clinical trials. Some of these compounds are active in both drug sensitive and drug resistant lung cancers. They also produce synergistic growth inhibition when combined with cytotoxic chemotherapeutic agents. Thus, these compounds may provide a new way to overcome drug resistance in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0000853486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000853486&partnerID=8YFLogxK

U2 - 10.1016/S1368-7646(98)80013-7

DO - 10.1016/S1368-7646(98)80013-7

M3 - Article

VL - 1

SP - 377

EP - 388

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 6

ER -